PFNX PFENEX INC

Pfenex to Present at the Liolios 7th Annual Gateway Conference

Pfenex to Present at the Liolios 7th Annual Gateway Conference

SAN DIEGO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the Liolios 7th Annual Gateway Conference in San Francisco, CA.

President and Chief Executive Officer, Eef Schimmelpennink, is scheduled to present on Wednesday, September 5, 2018 at 4:00 PM PT.

Interested parties can access the live audio webcast and archive for this presentation from the Investors Section of Pfenex's website at .

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (/), our investor relations website (/), press releases, SEC filings, public conference calls, corporate Twitter account (/pfenex), Facebook page (/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Pfenex Inc.

We are a clinical-stage development and licensing biotechnology company focused on leveraging our Pfēnex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, we have created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Our lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and our novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, we are developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.

Company Contact:

Susan A. Knudson

Chief Financial Officer

(858) 352-4324

EN
04/09/2018

Underlying

PFNXPFENEX INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PFENEX INC

 PRESS RELEASE
Free
PFNX PFENEX INC

Pfenex Reports Second Quarter 2020 Results and Provides Business Updat...

Pfenex Reports Second Quarter 2020 Results and Provides Business Update Commercialization and launch of first royalty bearing products position company for next phase of growthMultiple U.S. health plans add Teriparatide Injection to their formulary upon its June 2020 launch as Pfenex and Alvogen continue to pursue therapeutic equivalence designation; Received EU CHMP positive opinionPfenex enters into new research collaboration and license agreement with Merck & Co. Inc., with the potential to earn up to $293M in upfront, development, and sales milestonesReceipt of India Marketing Authoriza...

August 6, 2020 1 EN
 PRESS RELEASE
Free
PFNX PFENEX INC

Pfenex to Announce Second Quarter Financial Results on August 6

Pfenex to Announce Second Quarter Financial Results on August 6 SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Pfenex will host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 PM Pacific Time (4:30 PM Eastern Time). Conference Call & Webcast Thursday, August 6th @ 1:30 PM Pacific Time (4:30 PM Eastern Time) Domestic:       877-705-6003 (Domestic...

July 20, 2020 1 EN
 PRESS RELEASE
Free
PFNX PFENEX INC

Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Na...

Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business Update Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorizationPfenex’s commercial partner Adalvo entered into commercialization agreement in Latin America for PF708 with a large, multinational pharmaceutical firmSerum Institute of India is awarded first UNICEF supply agreement for Pneumosil®Merck announces safety and immunogenicity objectives were met ...

June 26, 2020 1 EN
 PRESS RELEASE
Free
PFNX PFENEX INC

Pfenex Announces U.S. Commercial Launch of Teriparatide Injection

Pfenex Announces U.S. Commercial Launch of Teriparatide Injection Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United StatesThe first FDA-approved teriparatide with Forteo® 1-3 as the reference drug SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.  Teriparatide Injection (also referred to as PF708 and Bonsity™) is a prescription medicine approved for several uses, including in postmenopausa...

June 12, 2020 1 EN
 PRESS RELEASE
Free
PFNX PFENEX INC

Pfenex to Participate in the William Blair Growth Stock Conference

Pfenex to Participate in the William Blair Growth Stock Conference SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat at the William Blair Growth Stock Conference on June 9, 2020.  The discussion will be virtual and accessible at . Presentation Details:Date: Tuesday, June 9, 2020Time:9:20 am – 9:50 am Central Time (7:20 am – 7:50 am Pacific Time)Link:  Interested parties can access the live audio webcast and archive from the Investors Section of...

June 5, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch